With 4.48 million shares changed hands, the volume of the stock remained heavier than its average volume of 3.25 million shares. During the session, the Drug Manufacturers – General company that operates in wider Healthcare sector, reached to the highest price of $802.51 whereas the lowest price it dropped to was $778.19. The 52-week range on LLY shows that it touched its highest point at $972.53 and its lowest point at $561.65 during that stretch. It currently has a 1-year price target of $1018.35. With its current market cap of 757.03 billion, LLY has annualized dividend of $5.03 while the current yield stands at 0.63%. LLY paid its most recent dividend on 1723680000, while the ex-dividend date for that was 1731628800. Beta for the stock currently stands at 0.41.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of LLY was down-trending over the past week, with a drop of -3.89%, but this was down by -13.30% over a month. Three-month performance dropped to -10.57% while six-month performance rose 3.36%. The stock gained 32.92% in the past year, while it has gained 36.80% so far this year. A look at the trailing 12-month EPS for LLY yields 9.14 with Next year EPS estimates of 22.62. For the next quarter, that number is 5.46. This implies an EPS growth rate of 109.72% for this year and 70.67% for next year. EPS is expected to grow by 33.80% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 13.74%.
Float and Shares Shorts:
At present, 949.38 million LLY shares are outstanding with a float of 850.72 million shares on hand for trading. On 2024-10-15, short shares totaled 5.79 million, which was 64.0 higher than short shares on 1726185600. In addition to Mr. David A. Ricks as the firm’s Chairman, CEO & President, Dr. Daniel M. Skovronsky M.D., Ph.D. serves as its EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology.
Institutional Ownership:
Through their ownership of 0.83726 of LLY’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, LLY reported revenue of $11439100000.0 and operating income of $4434400000.0. The EBITDA in the recently reported quarter was $5043500000.0 and diluted EPS was $1.07.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for LLY since 19 analysts follow the stock currently. There are 17 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With LLY analysts setting a high price target of 1250.0 and a low target of 700.0, the average target price over the next 12 months is 996.13. Based on these targets, LLY could surge 56.75% to reach the target high and fall by -12.22% to reach the target low. Reaching the average price target will result in a growth of 24.91% from current levels.
Analysts have provided yearly estimates in a range of $13.36489 being high and $13.08352 being low. For LLY, this leads to a yearly average estimate of $13.25435. The surprise factor in the prior quarter was $2.6. Based on analyst estimates, the high estimate for the next quarter is $4.95 and the low estimate is $4.9. The average estimate for the next quarter is thus $4.92.
